Sourcing comparison · Pharmaceutical Ingredients (API)
Tariff & fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
| Annual import value | Estimated duty & fee savings / year |
|---|---|
| $50,000 | $2,374 |
| $250,000 | $11,869 |
| $1,000,000 | $47,475 |
Savings scale linearly with volume. Enter your exact figure to model it.
Calculate your exact volume →If your pharmaceutical ingredients (api) currently ships from China, the duty bill is worth a second look. China carries roughly 14.5% in duties and fees against 10% for Italy, a spread worth near $4,748 on $100,000 of annual volume. For a category this exposed to surcharges, the sourcing map is effectively a pricing map. What follows is the layer-by-layer comparison, the trade context behind each rate, and how the gap grows with volume.
Consider what each country's goods actually face at the border. China-made goods carry a 2% Most-Favoured-Nation base duty and a 12.5% forced-labor Section 301 duty on its pharmaceutical ingredients (api), an effective 14.5% once the $49.74 in processing fees are added. A Italy origin attracts a 2% Most-Favoured-Nation base duty and an 8% forced-labor Section 301 duty on its pharmaceutical ingredients (api), an effective 10% once the $49.74 in processing fees are added. Because the MPF and HMF ($49.74 combined) track customs value rather than origin, they wash out of the comparison entirely. That leaves a $474.75 gap on every $10,000 of goods, driven entirely by the 4.5% spread in effective duty rate. Scaled up, expect near $1,187 per $25,000 order and around $4,748 once annual buying reaches $100,000. Scaled to a single $25,000 PO, the gap is near $1,187, repeated on every reorder.
The category, HTS 2934, 2935, 2936, 2937, 2938, 2939, 2940, 2941, takes in Antibiotic APIs, Analgesic APIs, Cardiovascular APIs, Oncology ingredients, Vitamin synthesis intermediates, Steroid hormones, and Insulin precursors among other pharmaceutical ingredients (api). For pharmaceutical ingredients (api), where buyers reorder frequently, the duty rate compounds into one of the largest controllable costs on the P&L. Pharmaceutical ingredient tariffs directly affect US drug prices and supply security; the agricultural-adjacent Section 122 carve-out this category carried is moot now that the surcharge itself lapsed to 0% sitewide on July 24, 2026. A Asia-Pacific supplier, China concentrates its US exports in consumer electronics, computers servers, and clothing garments. With no preferential deal in force, China pharmaceutical ingredients (api) faces the standard rates plus any applicable surcharge. Italy's trade profile leans toward industrial machinery, passenger vehicles, and pharmaceuticals, and it sits in Europe. Italy trades under the EU bilateral framework, which shapes the duties on its pharmaceutical ingredients (api). Moving between Asia-Pacific and Europe changes more than duty, so treat the tariff saving as one input among several. A switch to Italy still hinges on capacity, certification and lead time, but the duty advantage is the part that is already quantified. With the US running its highest average tariff in decades, concentrated exposure to one high-duty origin is now a measurable annual cost rather than an abstract risk.
For $100,000 a year of pharmaceutical ingredients (api), the move from China to Italy is worth about $4,748, scaling to $2,374 at $50,000, $11,869 at $250,000, and $47,475 at $1,000,000. The numbers come straight from the landed-cost engine, with product cost and shipping fixed across both origins to isolate the tariff difference. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier. If any price premium from Italy is smaller than the duty saving, the switch still wins on net landed cost. A quick checklist for the Italy option: match the HTS classification, get a quote that itemises duty apart from freight, and check for any antidumping or countervailing order on your item. Because rates move, treat this as a point-in-time read and re-check before committing — new proclamations and bilateral deals can shift the stack with little notice. Use the Tariff Savings Finder to test your real numbers and see alternatives beyond Italy.
At $100,000 of annual import value, switching from China to Italy saves an estimated $4,748 in duties and fees, because the effective tariff rate falls from 14.5% to 10%. The saving scales linearly with volume. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
Italy-origin pharmaceutical ingredients (api) is assessed a 2% Most-Favoured-Nation base duty and an 8% forced-labor Section 301 duty, for an effective 10% duty rate before the Merchandise Processing Fee ($36.55) and Harbor Maintenance Fee ($13.19).
China carries an effective 14.5% rate versus 10% for Italy. The gap comes from differences in the base, Section 232 and bilateral rates that apply to each origin.
Tariff rates from Tax Foundation, USITC, and Penn Wharton Budget Model; retaliatory data from the retaliating governments' official gazettes and registers; industry data from the U.S. Census Bureau (NAICS). Last verified .